Notice2024-28024
Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production Activity; PCI Pharma Services; (Pharmaceutical Products); Croydon and Philadelphia, Pennsylvania
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 29, 2024
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 230 (Friday, November 29, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 230 (Friday, November 29, 2024)]
[Notices]
[Page 94704]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-28024]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-58-2024]
Foreign-Trade Zone (FTZ) 35, Notification of Proposed Production
Activity; PCI Pharma Services; (Pharmaceutical Products); Croydon and
Philadelphia, Pennsylvania
PCI Pharma Services (PCI) submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facilities in
Croydon, Pennsylvania and Philadelphia, Pennsylvania within Subzone
35L. The notification conforming to the requirements of the Board's
regulations (15 CFR 400.22) was received on November 21, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished product includes: cendakimab dosages packed
in single and multi-dose packaging (duty-free).
The proposed foreign-status material/component includes: bulk
cendakimab in filled syringes (duty-free).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#caacbeb08abeb8abaeafe4ada5bc"><span class="__cf_email__" data-cfemail="f99f8d83b98d8b989d9cd79e968f">[email protected]</span></a>. The closing period for their receipt is January 8, 2025.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Kolade Osho at
<a href="/cdn-cgi/l/email-protection#49022625282d2c67063a2126093d3b282d2c672e263f"><span class="__cf_email__" data-cfemail="38735754595c5d16774b5057784c4a595c5d165f574e">[email protected]</span></a>.
Dated: November 22, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-28024 Filed 11-27-24; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 29, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.